MX2018009904A - Escision de secuencias de acido nucleico retrovirales. - Google Patents
Escision de secuencias de acido nucleico retrovirales.Info
- Publication number
- MX2018009904A MX2018009904A MX2018009904A MX2018009904A MX2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A
- Authority
- MX
- Mexico
- Prior art keywords
- excision
- nucleic acid
- acid sequences
- retroviral nucleic
- compositions
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title 1
- 108091033409 CRISPR Proteins 0.000 abstract 2
- 208000031873 Animal Disease Models Diseases 0.000 abstract 1
- 238000010354 CRISPR gene editing Methods 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000011558 animal model by disease Methods 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295390P | 2016-02-15 | 2016-02-15 | |
| US201662298722P | 2016-02-23 | 2016-02-23 | |
| US201662337994P | 2016-05-18 | 2016-05-18 | |
| US201662345520P | 2016-06-03 | 2016-06-03 | |
| US201662363625P | 2016-07-18 | 2016-07-18 | |
| US201662410496P | 2016-10-20 | 2016-10-20 | |
| PCT/US2017/017652 WO2017142835A1 (en) | 2016-02-15 | 2017-02-13 | Excision of retroviral nucleic acid sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009904A true MX2018009904A (es) | 2019-07-08 |
Family
ID=59626223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009904A MX2018009904A (es) | 2016-02-15 | 2017-02-13 | Escision de secuencias de acido nucleico retrovirales. |
| MX2023005397A MX2023005397A (es) | 2016-02-15 | 2018-08-15 | Escision de secuencias de acido nucleico retrovirales. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005397A MX2023005397A (es) | 2016-02-15 | 2018-08-15 | Escision de secuencias de acido nucleico retrovirales. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12122997B2 (OSRAM) |
| EP (1) | EP3417062B1 (OSRAM) |
| JP (1) | JP7176737B2 (OSRAM) |
| CN (1) | CN109415728A (OSRAM) |
| AU (1) | AU2017219605B2 (OSRAM) |
| CA (1) | CA3014631A1 (OSRAM) |
| MX (2) | MX2018009904A (OSRAM) |
| WO (1) | WO2017142835A1 (OSRAM) |
| ZA (2) | ZA201806060B (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| CA2922428A1 (en) | 2013-08-29 | 2015-03-05 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3919622A1 (en) | 2015-06-01 | 2021-12-08 | Temple University - Of The Commonwealth System of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| CN109415728A (zh) | 2016-02-15 | 2019-03-01 | 天普大学-联邦高等教育系统 | 逆转录病毒核酸序列的切除 |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3942043A2 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4114937A4 (en) | 2020-03-04 | 2024-09-04 | Flagship Pioneering Innovations VI, LLC | METHODS AND COMPOSITIONS FOR MODULATING A GENOME |
| CN113528514B (zh) * | 2020-04-22 | 2023-05-05 | 中国科学院分子植物科学卓越创新中心 | 基于CRISPR-Cas12a干预阻断病毒逆转录转座的技术 |
| BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| WO2022071974A1 (en) * | 2020-10-02 | 2022-04-07 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of herpes simplex type i and other related human herpesviruses |
| WO2022232442A2 (en) * | 2021-04-28 | 2022-11-03 | Salk Institute For Biological Studies | Multiplex crispr/cas9-mediated target gene activation system |
| EP4347035A4 (en) * | 2021-06-01 | 2025-09-03 | Univ Massachusetts | CAS9 NICKING-MEDIATED GENE EDITING |
| WO2023010061A1 (en) * | 2021-07-27 | 2023-02-02 | University Of Miami | Nanoparticles and uses thereof for treatment of human immunodeficiency virus |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| WO2026039311A1 (en) | 2024-08-10 | 2026-02-19 | Vectorgen | Lentiviral vector for treating human immunodeficiency virus infection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| WO2011043830A2 (en) | 2009-10-09 | 2011-04-14 | New York University | Methods, agents and peptides for inducing an innate immune response in hiv vaccination |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| IL239317B (en) * | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
| CA2922428A1 (en) * | 2013-08-29 | 2015-03-05 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for rna-guided treatment of hiv infection |
| CN104726449A (zh) | 2015-03-23 | 2015-06-24 | 国家纳米科学中心 | 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途 |
| CN109415728A (zh) | 2016-02-15 | 2019-03-01 | 天普大学-联邦高等教育系统 | 逆转录病毒核酸序列的切除 |
-
2017
- 2017-02-13 CN CN201780023772.9A patent/CN109415728A/zh active Pending
- 2017-02-13 JP JP2018543090A patent/JP7176737B2/ja active Active
- 2017-02-13 WO PCT/US2017/017652 patent/WO2017142835A1/en not_active Ceased
- 2017-02-13 CA CA3014631A patent/CA3014631A1/en active Pending
- 2017-02-13 MX MX2018009904A patent/MX2018009904A/es unknown
- 2017-02-13 AU AU2017219605A patent/AU2017219605B2/en active Active
- 2017-02-13 US US15/998,558 patent/US12122997B2/en active Active
- 2017-02-13 EP EP17753686.9A patent/EP3417062B1/en active Active
-
2018
- 2018-08-15 MX MX2023005397A patent/MX2023005397A/es unknown
- 2018-09-10 ZA ZA2018/06060A patent/ZA201806060B/en unknown
-
2020
- 2020-07-10 US US16/926,427 patent/US20200392487A1/en not_active Abandoned
-
2022
- 2022-06-01 ZA ZA2022/06102A patent/ZA202206102B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201806060B (en) | 2023-01-25 |
| EP3417062A4 (en) | 2019-12-11 |
| AU2017219605B2 (en) | 2023-04-13 |
| US20190225963A1 (en) | 2019-07-25 |
| US20200392487A1 (en) | 2020-12-17 |
| MX2023005397A (es) | 2023-05-19 |
| JP2019504868A (ja) | 2019-02-21 |
| CA3014631A1 (en) | 2017-08-24 |
| AU2017219605A1 (en) | 2018-09-20 |
| JP7176737B2 (ja) | 2022-11-22 |
| WO2017142835A1 (en) | 2017-08-24 |
| CN109415728A (zh) | 2019-03-01 |
| EP3417062A1 (en) | 2018-12-26 |
| EP3417062B1 (en) | 2024-06-26 |
| ZA202206102B (en) | 2023-09-27 |
| US12122997B2 (en) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206102B (en) | Excision of retroviral nucleic acid sequences | |
| JOP20210231A1 (ar) | مركبات ترابطية مستهدفة كمركبات علاجية | |
| EP4406585A3 (en) | Nucleic acid products and methods of administration thereof | |
| MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
| FIC20250001I1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| MX2023006105A (es) | Ligandos de direccion. | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| EP4249036A3 (en) | Methods and products for nucleic acid production and delivery | |
| CN105593367A8 (zh) | CRISPR‑Cas9特异性敲除猪SLA‑1基因的方法及用于特异性靶向SLA‑1基因的sgRNA | |
| EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| HUE055002T2 (hu) | Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra | |
| MX2022013010A (es) | Composiciones y metodos para inhibir la expresion genica de lpa. | |
| MX2021014368A (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
| WO2015112896A3 (en) | Methods and compositions for sequences guiding cas9 targeting | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| EP4644567A3 (en) | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use | |
| SG10201805815YA (en) | Rna-guided gene drives | |
| IL280962A (en) | Methods for delivering gene editing reagents to cells within organs | |
| PT3233129T (pt) | Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições | |
| MX2017000143A (es) | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos. | |
| JOP20200230A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
| CY1120084T1 (el) | Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| WO2016048861A3 (en) | Heterocyclic compounds and use thereof |